HARTFORD — Aetna, a CVS Health company, and Fresenius Medical Care North America (FMCNA) today announced they have enhanced their value-based care agreement to support the health care needs of Aetna Medicare Advantage members with end-stage renal disease (ESRD). FMCNA provides support services that focus on the full continuum of care for approximately 4,500 Aetna ESRD members, resulting in reduced hospitalizations and improved patient outcomes.
The enhanced value-based agreement includes additional incentives that align health care reimbursement with quality performance and reduction of total cost of care to deliver greater value to Aetna Medicare Advantage members. Quality performance measures in this arrangement support Aetna with the Centers for Medicare & Medicaid Services (CMS) Star Ratings initiative, with measures of quality of health and drug services. The companies are also developing unique ESRD performance metrics tied to CMS quality measures for this population. Aetna Medicare Advantage members with ESRD will continue to have access to FMCNA’s more than 2,600 dialysis centers and home dialysis options to help them lead fuller, more active lives. The value-based care agreement was effective January 1, 2021.
This agreement also aligns with the 21st Century Cures Act, which opens the door for previously ineligible ESRD patients to enroll in a Medicare Advantage plan beginning January 1, 2021.
“Kidney disease affects millions of people and requires personalized treatment options that are right for them,” said Angie Meoli, SVP, Network Strategy and Provider Experience at Aetna. “Aetna and FMCNA have had a longstanding relationship, collaborating to help Aetna Medicare Advantage members with ESRD receive the care needed to live healthy and productive lives. Value-based arrangements, like we’ve established with FMCNA, will continue to be essential for supporting chronic care patients with quality, affordable care when they need it most.”
“Aetna has been a great partner in our mutual goal to improve the quality of care and outcomes for our patients while reducing total costs to the health care system,” said David Pollack, President of FMCNA’s Integrated Care Group. “Together with our physician partners in InterWell Health, a national network of high-performing nephrologists focused on value-based care, we are confident we can build upon the success reached over the past six years to positively impact the lives of patients living with kidney disease.”
More than 785,000 Americans are living with kidney failure, with more than 554,000 relying on life-sustaining dialysis.Treatment can be challenging and costly for both patients and payers. Aetna is committed to finding solutions that improve the lives of members with chronic kidney disease and reducing overall medical costs through collaborations with providers such as FMCNA and through CVS Kidney Care, a kidney care leader offering a complete approach to treatment.